{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"162","value":"36.2"},{"groupId":"OG001","spread":"1380","value":"203"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"55"}],"units":"Participants"}],"title":"Predose"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"1410","value":"1370"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"46"}],"units":"Participants"}],"title":"15 minutes after start of infusion"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1900","value":"1640"},{"groupId":"OG001","spread":"928","value":"1130"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"51"}],"units":"Participants"}],"title":"End of infusion"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"293","value":"104"},{"groupId":"OG001","spread":"2300","value":"480"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"46"}],"units":"Participants"}],"title":"30 minutes after end of infusion"}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"55"}],"units":"Participants"}],"description":"Concentrations of carfilzomib in plasma were measured using a validated assay method. The lower limit of quantification was 0.100 ng/mL.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received carfilzomib administered by intravenous (IV) infusion on days 1, 2, 8, 9, 15, and 16 of each 28-day cycle (20 mg/m² on days 1 and 2 of cycle 1 and 27 mg/m² thereafter).\n\nParticipants also received 40 mg dexamethasone IV or orally on days 1, 8, 15 and 22 for the first 8 cycles; starting with cycle 9, dexamethasone was administered only on days 1, 8, and 15.","id":"OG000","title":"Twice-weekly Carfilzomib 20/27 mg/m² + Dexamethasone"},{"description":"Participants received carfilzomib administered by IV infusion on days 1, 8, and 15 of each 28-day cycle (20 mg/m² on day 1 of cycle 1 and 70 mg/m² thereafter).\n\nParticipants also received 40 mg dexamethasone IV or orally on days 1, 8, 15 and 22 for the first 8 cycles; starting with cycle 9, dexamethasone was administered only on days 1, 8, and 15.","id":"OG001","title":"Once-weekly Carfilzomib 20/70 mg/m² + Dexamethasone"}],"paramType":"MEAN","populationDescription":"Participants at a subset of sites who participated in the sparse pharmacokinetic sampling, with available data at each time point.","reportingStatus":"POSTED","timeFrame":"Cycle 2 day 1 predose, 15 minutes after the start of infusion (once-weekly carfilzomib only), end of infusion, and 30 minutes after the end of infusion","title":"Plasma Carfilzomib Concentration During Cycle 2","type":"SECONDARY","unitOfMeasure":"ng/mL"}